Correlates of cervical mucosal antibodies to human papillomavirus 16: Results from a case control study

被引:17
作者
Bierl, C
Karem, K
Poon, AC
Swan, D
Tortolero-Luna, G
Follen, M
Wideroff, L
Unger, ER [1 ]
Reeves, WC
机构
[1] Ctr Dis Control & Prevent, Viral Exanthems & Herpesvirus Branch, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[3] Univ Texas, Sch Publ Hlth, Houston, TX 77030 USA
[4] NCI, Appl Res Branch, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1016/j.ygyno.2005.07.100
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background While the cervical mucosal immune response to human papillomavirus (HPV) infection is believed to be central to viral clearance, it is not well characterized. We performed this analysis to determine correlates of HPV-16-specific mucosal antibody response in women at high risk for infection with HPV. Methods. Cervical mucosal and serum samples were obtained from participants in a case control study that measured demographic risk factors of cervical disease and HPV infection. An HPV-16 L1-virus-like particle ELISA was used to detect HPV-16-specific IgA and IgG. Antibody results were correlated to demographic characteristics, sexual history, cervical disease, and HPV detection. Results. Cervical anti-HPV-16 IgA and IgG inversely correlated with HPV DNA, HPV-16 DNA, and cervical disease. Conclusions. These findings suggest that mucosal antibodies may protect against HPV infection and cervical disease. However additional longitudinal studies evaluating serum and mucosal antibody correlates of incident, persistent, and clearing HPV infection are needed. In addition, standardization of mucosal sample collection and testing methods are required.
引用
收藏
页码:S262 / S268
页数:7
相关论文
共 17 条
[1]   Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia II. Systemic but not local IgA responses correlate with clearance of HPV-16 [J].
Bontkes, HJ ;
de Gruijl, TD ;
Walboomers, JMM ;
Schiller, JT ;
Dillner, J ;
Helmerhorst, TJM ;
Verheijen, RHM ;
Scheper, RJ ;
Meijer, CJLM .
JOURNAL OF GENERAL VIROLOGY, 1999, 80 :409-417
[2]   Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection [J].
Carter, JJ ;
Koutsky, LA ;
Hughes, JP ;
Lee, SK ;
Kuypers, J ;
Kiviat, N ;
Galloway, DA .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1911-1919
[3]   Detection of cervical antibodies to human papillomavirus type 16 (HPV-P6) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions [J].
Hagensee, ME ;
Koutsky, LA ;
Lee, SK ;
Grubert, T ;
Kuypers, J ;
Kiviat, NB ;
Galloway, DA .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04) :1234-1239
[4]   Specific serologic response to genital human papillomavirus types in patients with vulvar precancerous and cancerous lesions [J].
Heim, K ;
Widschwendter, A ;
Szedenik, H ;
Geier, A ;
Christensen, ND ;
Bergant, A ;
Concin, N ;
Höpfl, R .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (04) :1073-1083
[5]   Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles [J].
Ho, GYF ;
Studentsov, Y ;
Hall, CB ;
Bierman, R ;
Beardsley, L ;
Lempa, M ;
Burk, RD .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (06) :737-742
[6]   Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay [J].
Karem, KL ;
Poon, AC ;
Bierl, C ;
Nisenbaum, R ;
Unger, E .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2002, 9 (03) :577-582
[7]   Immunity to oncogenic human papillomaviruses [J].
Konya, J ;
Dillner, J .
ADVANCES IN CANCER RESEARCH, VOL 82, 2001, 82 :205-238
[8]   A controlled trial of a human papillomavirus type 16 vaccine [J].
Koutsky, LA ;
Ault, KA ;
Wheeler, CM ;
Brown, DR ;
Barr, E ;
Alvarez, FB ;
Chiacchierini, LM ;
Jansen, KU .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1645-1651
[9]   Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine [J].
Nardelli-Haefliger, D ;
Lurati, F ;
Wirthner, D ;
Spertini, F ;
Schiller, JT ;
Lowy, DR ;
Ponci, F ;
De Grandi, P .
VACCINE, 2005, 23 (28) :3634-3641
[10]   Immune responses to human papillomavirus in genital tract of women with cervical cancer [J].
Nguyen, HH ;
Broker, TR ;
Chow, LT ;
Alvarez, RD ;
Vu, HL ;
Andrasi, J ;
Brewer, LR ;
Jin, G ;
Mestecky, J .
GYNECOLOGIC ONCOLOGY, 2005, 96 (02) :452-461